Clinical and epidemiological rationale for prevention of uterus cancer
https://doi.org/10.33667/2078-5631-2020-4-59-62
Abstract
Introduction. Malignant neoplasms of the reproductive system dominate the structure of cancer incidence in women in the Russian Federation. In the structure of oncogynecological diseases, uterine body cancer (UBC) leads the way.
The purpose of the study: to analyze the dynamics of UBC incidence in the Omsk region in comparison with data for the Russian Federation in 2002–2018 years to determine the priorities of cancer prevention.
Results. There was a moderate tendency to increase the incidence of UBC in the region (Rg. = +1.8 %; p < 0.001) and for the Russian Federation (Rg. = +1.7 %; p < 0.001). The maximum percentage was among patients of 60–69 years old (32.3 %). There was a moderate trend in increasing UBC among women of 30–39 years old, and in the group of women of 35–39 years old there was a distinct trend in increasing the incidence (Rg. = +5.6 %; p < 0.050). The article presents the epidemiological features of UBC in comparison with cervical cancer in the region: the increase in the incidence of UBC (Rg. =+1.8 %) and the stability of the indicator at cervical cancer (Rg. = +0.050 %), the trend to rejuvenate both locations of cancer.
Conclusion. In Omsk Region, there is a unidirectional increase in the incidence of UBC with the Russian Federation, a trend in rejuvenating the disease, which dictates the need for cancer prevention in the practice of an obstetrician-gynecologist.
References
1. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. илл. 250 с.
2. Cancer Today – IARC, World Health Organization: GLOBOCAN 2018. gco.iarc.fr/today/home.
3. Клинышкова Т. В., Турчанинов Д. В., Самосудова И. Б. Эпидемиологические аспекты цервикального предрака у женского населения г. Омска (по материалам выборочного исследования) // Росс. вестник акушера-гинеколога. – 2013; 4: 13–17.
4. Думановская М. Р., Чернуха Г. Е., Асатурова А. В. и др. Частота выявления и структура гиперплазии эндометрия в различные возрастные периоды // Акушерство и гинекология. – 2015; 3: 40–44.
5. Клинышкова Т. В., Турчанинов Д. В., Буян М. С. Эпидемиологические аспекты рака шейки матки в Омской области // Акушерство и гинекология. – 2018; 3: 102–8.
6. Marnach ML, Butler KA, Henry MR et al. Oral Progestogens Versus Levonorge strel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. J Womens Health (Larchmt). 2017; 26 (4): 368–373. DOI: 10.1089/jwh.2016.5774.
7. Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. // Аm J Obstet Gynecol. – 2010; 203 (6): 547. e1–10. DOI: 10.1016/j.ajog.2010.07.037.
8. Gallos ID, Krishan P, Shehmar M et al. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. // Hum Reprod. – 2013; 28 (11): 2966–71. DOI: 10.1093/humrep/det320.
9. Management of Endometrial Hyperplasia. Greentop Guideline No. 67 RCOG/BSGE Joint Guideline February 2016 www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf.
10. Ørbo A, Arnes M, Vereide AB et al. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens // BJOG – 2016; 123 (9): 1512–9. DOI: 10.1111/1471–0528.13763.
11. Тихомиров А. Л. Обоснование использования комбинированных оральных контрацептивов для профилактики рецидивов типичных гиперплазий эндометрия // Гинекология. – 2018; 20 (4): 26–28.
12. Гиперпластические процессы эндометрия. Гинекология. Национальное руководство. 2017. М. с. 303–308.
13. Состояние онкологической помощи населению России в 2018 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. илл. 236 с.
Review
For citations:
Klinyshkova T.V. Clinical and epidemiological rationale for prevention of uterus cancer. Medical alphabet. 2020;(4):59-62. (In Russ.) https://doi.org/10.33667/2078-5631-2020-4-59-62
Views:
370
Email this article 